- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Results
570
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
570 companies
Synairgen
Market Cap: US$110.3k
Synairgen plc discovers and develops drugs for respiratory diseases.
SYGG.F
US$0.0001
7D
0%
1Y
-99.8%
Autolus Therapeutics
Market Cap: US$399.2m
A clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
AUTL
US$1.50
7D
-14.3%
1Y
-61.8%
Dogwood Therapeutics
Market Cap: US$9.5m
A development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
DWTX
US$4.96
7D
0.2%
1Y
2.3%
GT Biopharma
Market Cap: US$3.3m
A clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms.
GTBP
US$0.93
7D
-15.8%
1Y
-56.5%
Spero Therapeutics
Market Cap: US$116.5m
A clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
SPRO
US$2.07
7D
10.7%
1Y
51.1%
NextCure
Market Cap: US$13.5m
A clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.
NXTC
US$5.03
7D
-1.9%
1Y
-71.5%
Marker Therapeutics
Market Cap: US$12.0m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$0.93
7D
-28.2%
1Y
-74.4%
Athira Pharma
Market Cap: US$15.3m
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
ATHA
US$0.39
7D
-2.4%
1Y
-87.4%
Quoin Pharmaceuticals
Market Cap: US$4.3m
A late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
QNRX
US$7.38
7D
2.4%
1Y
-66.3%
Shuttle Pharmaceuticals Holdings
Market Cap: US$3.5m
A clinical stage pharmaceutical company, develops novel therapies to cure cancers.
SHPH
US$3.30
7D
-4.0%
1Y
-93.2%
Acurx Pharmaceuticals
Market Cap: US$7.3m
A clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
ACXP
US$4.62
7D
-2.0%
1Y
-89.5%
Candel Therapeutics
Market Cap: US$317.8m
A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients.
CADL
US$5.79
7D
-2.7%
1Y
-14.2%
Scinai Immunotherapeutics
Market Cap: US$1.4m
A biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel.
SCNI
US$1.53
7D
-4.4%
1Y
-59.0%
Pasithea Therapeutics
Market Cap: US$6.0m
A clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers.
KTTA
US$0.81
7D
12.7%
1Y
-82.2%
GRI Bio
Market Cap: US$3.5m
A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
GRI
US$1.39
7D
-0.7%
1Y
-83.9%
Bolt Biotherapeutics
Market Cap: US$9.8m
A clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
BOLT
US$5.13
7D
-0.4%
1Y
-62.1%
Revvity
Market Cap: US$10.5b
Provides health sciences solutions, technologies, and services worldwide.
RVTY
US$90.11
7D
-4.3%
1Y
-26.5%
VivoSim Labs
Market Cap: US$6.3m
A pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
VIVS
US$2.44
7D
15.6%
1Y
-64.9%
Jasper Therapeutics
Market Cap: US$45.5m
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.
JSPR
US$2.80
7D
-4.4%
1Y
-87.2%
Enveric Biosciences
Market Cap: US$3.7m
A biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
ENVB
US$1.13
7D
-7.4%
1Y
-85.2%
Iovance Biotherapeutics
Market Cap: US$806.9m
A commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
IOVA
US$2.23
7D
-17.1%
1Y
-80.9%
Ionis Pharmaceuticals
Market Cap: US$6.8b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$42.64
7D
-0.1%
1Y
-10.6%
Prelude Therapeutics
Market Cap: US$68.5m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.21
7D
-2.4%
1Y
-76.7%
eXoZymes
Market Cap: US$81.4m
Operates as a development stage biotechnology company.
EXOZ
US$9.70
7D
4.2%
1Y
n/a
Traws Pharma
Market Cap: US$9.9m
A clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
TRAW
US$1.40
7D
-0.7%
1Y
-84.9%
MetaVia
Market Cap: US$15.3m
A clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
MTVA
US$0.63
7D
-2.4%
1Y
-82.8%
BiomX
Market Cap: US$14.3m
A clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
PHGE
US$0.54
7D
-1.3%
1Y
-55.8%
Allarity Therapeutics
Market Cap: US$19.7m
A clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
ALLR
US$1.54
7D
63.0%
1Y
-71.7%
Imunon
Market Cap: US$15.0m
A clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.
IMNN
US$5.93
7D
-8.8%
1Y
-60.5%
Mirum Pharmaceuticals
Market Cap: US$3.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$73.87
7D
3.3%
1Y
71.4%
Pfizer
Market Cap: US$140.8b
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
PFE
US$24.76
7D
-4.3%
1Y
-14.7%
ICON
Market Cap: US$13.8b
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
ICLR
US$177.94
7D
1.2%
1Y
-44.7%
Gilead Sciences
Market Cap: US$140.2b
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
GILD
US$112.97
7D
-1.6%
1Y
43.0%
Biomea Fusion
Market Cap: US$116.0m
A clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
BMEA
US$1.95
7D
6.6%
1Y
-73.4%
Pluri
Market Cap: US$41.5m
A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.
PLUR
US$5.27
7D
-7.2%
1Y
-7.5%
IGC Pharma
Market Cap: US$39.2m
A clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.
IGC
US$0.43
7D
18.1%
1Y
19.9%